Feedback / Questions
Recentin (cediranib) - AstraZeneca
Lynparza (olaparib) - Merck (MSD), AstraZeneca
Lynparza + cediranib: Acceptance of regulatory submission in US for recurrent platinum-resistant ovarian cancer (based on CONCERTO trial) in H2 2020
(AstraZeneca)
-
Mar 22, 2020 -
Annual Report 2019
sNDA
https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-report-2019/pdf/AstraZeneca_AR_2019.pdf
Mar 22, 2020
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious